O-1812 is an eicosanoid derivative related to anandamide that acts as a potent and highly selective agonist for the cannabinoid receptor CB1, with a Ki of 3.4nM at CB1 and 3870nM at CB2.[1] Unlike most related compounds, O-1812 is metabolically stable against rapid breakdown by enzymes, and produces a cannabinoid-like discriminative effect in rats, which is similar but not identical to that produced by cannabinoid drugs of other chemical classes.[2][3][4][5]
See also [edit]
References [edit]
- ^ Di Marzo V, et al. (February 2001). "Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands". Biochemical and Biophysical Research Communications 281 (2): 444–51. doi:10.1006/bbrc.2001.4354. PMID 11181068.
- ^ Baskfield CY, Martin BR, Wiley JL (April 2004). "Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice". The Journal of Pharmacology and Experimental Therapeutics 309 (1): 86–91. doi:10.1124/jpet.103.055376. PMID 14718593.
- ^ Wiley JL, et al. (August 2004). "A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats". Experimental and Clinical Psychopharmacology 12 (3): 173–9. doi:10.1037/1064-1297.12.3.173. PMID 15301634.
- ^ Wiley JL, Smith FL, Razdan RK, Dewey WL (March 2005). "Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice". European Journal of Pharmacology 510 (1-2): 59–68. doi:10.1016/j.ejphar.2005.01.006. PMID 15740725.
- ^ Breivogel CS, et al. (July 2008). "Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice". Behavioural Pharmacology 19 (4): 298–307. doi:10.1097/FBP.0b013e328308f1e6. PMC 2751575. PMID 18622177.
|
|
|
| Phytocannabinoids |
|
|
Cannabinoid
metabolites |
|
|
Endogenous
cannabinoids |
|
|
Synthetic
cannabinoid
receptor
agonists |
Classical
cannabinoids
(Dibenzopyrans) |
|
|
Nonclassical
cannabinoids |
|
|
| Benzoylindoles |
|
|
| Naphthoylindoles |
|
|
| Naphthylmethylindoles |
|
|
| Phenylacetylindoles |
|
|
| Naphthoylpyrroles |
|
|
| Eicosanoids |
|
|
| Others |
|
|
|
Allosteric
modulators of
cannabinoid
receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid
receptor
antagonists and
inverse agonists |
|
|